01 January 2002
Level of antithrombin III, protein C, protein S and other selected parametersof coagulation and fibrinolysis in the blood of the patients with recurrent deep venous thrombosis.
Andrzej Swiatkiewicz, Piort Jurkowski, Maria Kotschy, Marek Ciecierski, Arkadiusz JawieńMed Sci Monit 2002; 8(4): CR263-268 :: ID: 420870
Abstract
BACKGROUND: Thrombophilia is caused mainly by disturbances of hemostasisinvolving excessive coagulation system activation, reduction of anticoagulation system (antithrombinIII, protein C, protein S, RAPC) or fibrinolytic activity. MATERIAL/METHODS: In 34 young patients (aged2 incidents) the activity of antithrombin III, proteinC, S, platelet count, adhesion and aggregation, APTT, stipven-kephalin, prothrombin time and INR wereinvestigated. Fibrinogen, factor XIII, ELT, FDP, Ag t-PA levels, antigen concentration and PAI-1 activitywere determined. Patients with idiopathic DVT, after elimination of most important thromboembolism riskfactors, were qualified for the study. DVT was confirmed in all patients by phlebography, plethysmographyand ultrasonography. Results were compared with a group of 54 healthy controls. RESULTS: In almost 50%of patients with recurrent DVT (15/34) decrease of at least one plasma coagulation inhibitor (AT III,PC, PS) level was observed. In the patient group (with AT III and/or PC and/or PS decrease) statisticallysignificant reduction of kaolin-kephalin time in comparison with controls was observed (α<0. 01). Analysis of fibrinolysis system demonstrated significant factor XIII level decrease (to 58.3%), fibrinogen level increase, ELT prolongation, and fibrinogen and fibrin degradation product increase in comparison with controls. The patients demonstrated 3-fold higher t-PA antigen level (13.1 ng/ml, α<0. 0001) and over 3-fold higher PAI-1 activity (26.7 AU/ml, α<0. 001) than healthy controls.
Conclusions: Reduced antithrombin III, protein C, protein S activity and excessive activation of the coagulation system with secondary fibrinolytic activity increase were found in patients with recurrent DVT.
Keywords: Antithrombin III, Blood Coagulation Tests, Fibrin Fibrinogen Degradation Products, Fibrinolysis, Phlebography, Plasminogen Activator Inhibitor 1, Platelet Function Tests, Plethysmography, Protein C, Protein S, Recurrence, Risk Factors, Thrombophilia, Tissue Plasminogen Activator, Venous Thrombosis
Editorial
01 April 2025 : Editorial
Editorial: Rapid Testing for the Avian Influenza A(H5N1) Virus is Urgently Required as Infections in Poultry and Dairy Cows are on the Rise, and so is Transmission to HumansDOI: 10.12659/MSM.949109
Med Sci Monit 2025; 31:e949109
In Press
Clinical Research
Serum Prolidase and Ischemia-Modified Albumin Levels in Neural Tube Defects: A Comparative Study of Myelome...Med Sci Monit In Press; DOI: 10.12659/MSM.947873
Clinical Research
Impact of Depression, Fatigue, and Pain on Quality of Life in Slovak Multiple Sclerosis PatientsMed Sci Monit In Press; DOI: 10.12659/MSM.947630
Clinical Research
Longitudinal Evaluation of Metabolic Benefits of Inactivated COVID-19 Vaccination in Diabetic Patients in T...Med Sci Monit In Press; DOI: 10.12659/MSM.947450
Clinical Research
Impact of Voltage Level on Hospitalization and Mortality in Electrical Injury Cases: A Retrospective Analys...Med Sci Monit In Press; DOI: 10.12659/MSM.947675
Most Viewed Current Articles
17 Jan 2024 : Review article 8,000,435
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,963
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 30,040
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 23,978
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912